RE:RE:RE:RE:RE:RE:Saltarelli is in the catbird seat... Yes, shareholders did demand that Rathjen avoid dilution. That was 4 years ago. Now, with 6% ownership on the horizon I see 94% dilution, with total loss of control.So, are you saying, poof, that Rathjen acted on shareholder wishes to do this?
Maybe I missed it, but I don't remember Rathjen petitioning the shareholders for help in the last 18 months.
Come on, even 50% dilution is better than total capitulation. Would there have been angel investors among the shareholders, or friends of shareholders, who would have helped? Or is the better solution for Rathjen and Saltarelli to allow Bioasis to get bought out by private interests so they can follow xB3 rather than having any responsibilities for making Bioasis and xB3 a success?
Don't make us laugh with your nonsense, poof. Even Midatech is promoting the huge value of xB3. So are you. What you're saying is that while owned by Bioasis shareholders xB3 is worthless but when owned by somebody else it's magically worth untold billions.
If I recall, Midatech is preaching a valuation of USD $50 billion per year or something.
Discount that by 99%. 1% is $500 million. Discount that by 95% due to a bad biotech market and by unrealized potential and you still get a valuation of USD $25 million, and you still arrive at a share price of almost 35¢ for BTI, seven times the 5¢ share price we're seeing now.
So is xB3 worthless or priceless?
Priceless, I think, which is why LT and The Placee want 75% of it, cheap, and why DrDR and The Other Dr is going along for the ride, because they also know the value, but don't want any responsibility for making something of xB3, or failing to do so.
jd